Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy

Immune checkpoint inhibitors (ICI) have created an advanced shift in the treatment of lung cancer (LC), but the existing biomarkers were not in clinical and widespread use. The purpose of this study was to develop a new nomogram with immune factors used for monitoring the response to ICI therapy. LC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xueping, He, Zhonglian, Liu, Wen, Han, Runkun, Li, Huilan, Dai, Shuqin, Zhang, Lin, Mao, Minjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095384/
https://www.ncbi.nlm.nih.gov/pubmed/35571492
http://dx.doi.org/10.1155/2022/9030782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095384/
https://www.ncbi.nlm.nih.gov/pubmed/35571492
http://dx.doi.org/10.1155/2022/9030782

Ejemplares similares